Search All News
A new drug that penetrates the protective barrier around pancreatic cancers and accumulates in malignant cells may improve current chemotherapy, a study in mice suggests.
Researchers in Columbia's medical and engineering schools have edited a strain of non-pathogenic bacteria to colonize solid tumors in mice and safely deliver potent immunotherapies.
Barring ovarian cancer surgery at low-volume hospitals could limit access to care for many rural and underserved patients, a new study has found.
- April 17, 2019
Leading physician and researcher, Lisa Kachnic, MD, will lead Columbia's department of radiation oncology.
- April 3, 2019
Anil Rustgi, the new director of the Herbert Irving Comprehensive Cancer Center, talks about new ideas in cancer research, the best patient care, and the importance of physician-scientists.
- February 20, 2019
A clinical trial at Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
- December 19, 2018
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
- December 10, 2018
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
- December 10, 2018
A new study suggests that a type of brain tumor in patients with neurofibromatosis type 1 could be treated with immunotherapy, which has so far proved ineffective in treating most brain cancers.
- October 31, 2018
A new study found that women with cervical cancer who had a radical hysterectomy with minimally invasive surgery had a significantly higher risk of death than those who had open surgery.
- October 12, 2018
For the second year, Velocity, Columbia's Ride to End Cancer raised more than $1 million for cancer care and research.